APA (7th ed.) Citation

P, J., SAA, N., N, T., JK, O., MA, H., Y, Z., . . . P, S. (2025). Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis. Clinical genitourinary cancer, 23(6), 102453. https://doi.org/10.1016/j.clgc.2025.102453

Chicago Style (17th ed.) Citation

P, Jain, et al. "Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis." Clinical Genitourinary Cancer 23, no. 6 (2025): 102453. https://doi.org/10.1016/j.clgc.2025.102453.

MLA (9th ed.) Citation

P, Jain, et al. "Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis." Clinical Genitourinary Cancer, vol. 23, no. 6, 2025, p. 102453, https://doi.org/10.1016/j.clgc.2025.102453.